Apricus Biosciences Announces First Quarter 2013 Financial Results Conference
Conference Call/Webcast to Be Held Friday, May 10, 2013 at 9:00 a.m. ET
SAN DIEGO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that it will hold a conference call to discuss its first quarter 2013
financial results and recent corporate highlights on Friday, May 10, 2013 at
9:00 a.m. ET. The Company expects to file its Form 10-Q for the quarter ended
March 31, 2013 with the Securities and Exchange Commission on Friday, May 10,
The call can be accessed in the U.S. by dialing 877-407-9210 and outside of
the U.S. by dialing 201-689-8049 and asking the conference operator for the
Apricus Bio Conference Call. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=170957. The teleconference
replay will be available for one week by dialing in the U.S. 877-660-6853 and
outside of the U.S. by dialing 201-612-7415.Replay Passcode 413843 is
required for playback. The webcast replay will be available for three months.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that
develops and markets innovative treatments that help large patient populations
across numerous, large-market therapeutic classes including male and female
sexual health. The Company has one approved product, Vitaros®, for the
treatment of erectile dysfunction, which will be marketed in Canada by Abbott
Laboratories, and Femprox®, a product candidate, for the treatment of female
sexual arousal disorder, which successfully completed one approximately
400-patient Phase III study in China.
For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations:
David Pitts or Lourdes Catala
Press spacebar to pause and continue. Press esc to stop.